Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab.
Martin SvatonMagdalena Knetki-WroblewskaSylwia TaborPetr DomeckyOndrej VenclicekJana KrejciMarie DrosslerovaMichal HrnciarikDaniel HricisakAlzbeta BejckovaOndrej FischerMartina VitkovaMaciej KrzakowskiPublished in: In vivo (Athens, Greece) (2024)
PD-L1 expression showed no significant effect on OS in patients with NSCLC with PD-L1≥50% treated with pembrolizumab.